|
1
|
Shin HR, Carlos MC and Varghese C: Cancer
control in the Asia Pacific region: Current status and concerns.
Jpn J Clin Oncol. 42:867–881. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Unger JM, Hershman DL, Martin D, Etzioni
RB, Barlow WE, LeBlanc M and Ramsey SR: The diffusion of docetaxel
in patients with metastatic prostate cancer. J Natl Cancer Inst.
107:1072014.
|
|
3
|
Bottomley MJ, Lo Surdo P, Di Giovine P,
Cirillo A, Scarpelli R, Ferrigno F, Jones P, Neddermann P, De
Francesco R, Steinkühler C, et al: Structural and functional
analysis of the human HDAC4 catalytic domain reveals a regulatory
structural zinc-binding domain. J Biol Chem. 283:26694–26704. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cao LL, Yue Z, Liu L, Pei L, Yin Y, Qin L,
Zhao J, Liu H, Wang H and Jia M: The expression of histone
deacetylase HDAC1 correlates with the progression and prognosis of
gastrointestinal malignancy. Oncotarget. 8:39241–39253.
2017.PubMed/NCBI
|
|
5
|
Putcha P, Yu J, Rodriguez-Barrueco R,
Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M,
Castro V, Llobet-Navas D, et al: Erratum to: HDAC6 activity is a
non-oncogene addiction hub for inflammatory breast cancers. Breast
Cancer Res. 19:492017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Meng J, Zhang HH, Zhou CX, Li C, Zhang F
and Mei QB: The histone deacetylase inhibitor trichostatin A
induces cell cycle arrest and apoptosis in colorectal cancer cells
via p53-dependent and -independent pathways. Oncol Rep. 28:384–388.
2012.PubMed/NCBI
|
|
7
|
Jeon HW and Lee YM: Inhibition of histone
deacetylase attenuates hypoxia-induced migration and invasion of
cancer cells via the restoration of RECK expression. Mol Cancer
Ther. 9:1361–1370. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Z, Tang F, Hu P, Wang Y, Gong J, Sun
S and Xie C: HDAC6 promotes cell proliferation and confers
resistance to gefitinib in lung adenocarcinoma. Oncol Rep.
36:589–597. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li A, Liu Z, Li M, Zhou S, Xu Y, Xiao Y
and Yang W: HDAC5, a potential therapeutic target and prognostic
biomarker, promotes proliferation, invasion and migration in human
breast cancer. Oncotarget. 7:37966–37978. 2016.PubMed/NCBI
|
|
10
|
Nagano T and Fraser P: No-nonsense
functions for long non-coding RNAs. Cell. 145:178–181. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen S, Liang H, Yang H, Zhou K, Xu L, Liu
J, Lai B, Song L, Luo H, Peng J, et al: LincRNa-p21: Function and
mechanism in cancer. Med Oncol. 34:982017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cao MX, Jiang YP, Tang YL and Liang XH:
The crosstalk between lncRNA and microRNA in cancer metastasis:
Orchestrating the epithelial-mesenchymal plasticity. Oncotarget.
8:12472–12483. 2017.PubMed/NCBI
|
|
13
|
Ishii N, Ozaki K, Sato H, Mizuno H, Saito
S, Takahashi A, Miyamoto Y, Ikegawa S, Kamatani N, Hori M, et al:
Identification of a novel non-coding RNA, MIAT, that confers
risk of myocardial infarction. J Hum Genet. 51:1087–1099. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shen S, Jiang H, Bei Y, Xiao J and Li X:
Long non-coding RNAs in cardiac remodeling. Cell Physiol Biochem.
41:1830–1837. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Crea F, Venalainen E, Ci X, Cheng H, Pikor
L, Parolia A, Xue H, Saidy Nur NR, Lin D, Lam W, et al: The role of
epigenetics and long non-coding RNA MIAT in neuroendocrine prostate
cancer. Epigenomics. 8:721–731. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sattari A, Siddiqui H, Moshiri F, Ngankeu
A, Nakamura T, Kipps TJ and Croce CM: Upregulation of long
non-coding RNA MIAT in aggressive form of chronic lymphocytic
leukemias. Oncotarget. 7:54174–54182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thrumurthy SG, Chaudry MA, Chau I and
Allum W: Does surgery have a role in managing incurable gastric
cancer? Nat Rev Clin Oncol. 12:676–682. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang R, Zeng Y, Xu H, Chen Z, Xiang M, Fu
Y, Yin Y, Zhong J, Zeng M, Wang P, et al: Heterogeneous nuclear
ribonucleoprotein K is overexpressed and associated with poor
prognosis in gastric cancer. Oncol Rep. 36:929–935. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pasechnikov V, Chukov S, Fedorov E,
Kikuste I and Leja M: Gastric cancer: Prevention, screening and
early diagnosis. World J Gastroenterol. 20:13842–13862. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ni W, Zhang Y, Zhan Z, Ye F, Liang Y,
Huang J, Chen K, Chen L and Ding Y: A novel lncRNA uc.134 represses
hepatocellular carcinoma progression by inhibiting CUL4A-mediated
ubiquitination of LATS1. J Hematol Oncol. 10:912017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang Y, Wang S and Li T: Altered long
non-coding RNAs predict worse outcome in osteosarcoma patients:
Evidence from a meta-analysis. Oncotarget. 8:35234–35243.
2017.PubMed/NCBI
|
|
22
|
Su DN, Wu SP, Chen HT and He JH: HOTAIR, a
long non-coding RNA driver of malignancy whose expression is
activated by FOXC1, negatively regulates miRNA-1 in hepatocellular
carcinoma. Oncol Lett. 12:4061–4067. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wuebben EL and Rizzino A: The dark side of
SOX2: Cancer - a comprehensive overview. Oncotarget. 8:44917–44943.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang K, Li Q, Kang X, Wang Y and Wang S:
Identification and functional characterization of lncRNAs acting as
ceRNA involved in the malignant progression of glioblastoma
multiforme. Oncol Rep. 36:2911–2925. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mottet D, Pirotte S, Lamour V, Hagedorn M,
Javerzat S, Bikfalvi A, Bellahcène A, Verdin E and Castronovo V:
HDAC4 represses p21WAF1/Cip1 expression in human cancer
cells through a Sp1-dependent, p53-independent mechanism. Oncogene.
28:243–256. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Seidel C, Schnekenburger M, Mazumder A,
Teiten MH, Kirsch G, Dicato M and Diederich M: 4-Hydroxybenzoic
acid derivatives as HDAC6-specific inhibitors modulating
microtubular structure and HSP90α chaperone activity against
prostate cancer. Biochem Pharmacol. 99:31–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang Y, Xu P, Yao J, Yang R, Shi Z, Zhu X,
Feng X and Gao S: MicroRNA-216b is down-regulated in human gastric
adenocarcinoma and inhibits proliferation and cell cycle
progression by targeting oncogene HDAC8. Target Oncol. 11:197–207.
2016. View Article : Google Scholar : PubMed/NCBI
|
